| Literature DB >> 31921691 |
Hongshi Cai1,2, Jiaxin Li1,2, Yadong Zhang1,2, Yan Liao1,2, Yue Zhu1,2, Cheng Wang1,2, Jinsong Hou1,2.
Abstract
Aerobic glycolysis is the main pathway for energy metabolism in cancer cells. It provides energy and biosynthetic substances for tumor progression and metastasis by increasing lactate production. Lactate dehydrogenase A (LDHA) promotes glycolysis process by catalyzing the conversion of pyruvate to lactate. Despite LDHA exhibiting carcinogenesis in various cancers, its role in oral squamous cell carcinoma (OSCC) remains unclear. This study demonstrated that LDHA was over-expressed in both OSCC tissues and cell lines, and was significantly associated with lower overall survival rates in patients with OSCC. Using weighted gene correlation network analysis and gene set enrichment analysis for the gene expression data of patients with OSCC (obtained from The Cancer Genome Atlas database), a close association was identified between epithelial-mesenchymal transition (EMT) and LDHA in promoting OSCC progression. The knockdown of LDHA suppressed EMT, cell proliferation, and migration and invasion of OSCC cells in vitro. Moreover, the silencing of LDHA inhibited tumor growth in vivo. Oxamate, as a competitive LDHA inhibitor, was also suppressed diverse malignant biocharacteristics of OSCC cells. Our findings reveal that LDHA acts as an oncogene to promote malignant progression of OSCC by facilitating glycolysis and EMT, and LDHA may be a potential anticancer therapeutic target.Entities:
Keywords: GSEA; LDHA; WGCNA; epithelial–mesenchymal transition; glycolysis; oral squamous cell carcinoma; oxamate
Year: 2019 PMID: 31921691 PMCID: PMC6930919 DOI: 10.3389/fonc.2019.01446
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1LDHA is up-regulated in OSCC and is associated with poor prognosis. (A) Representative immunohistochemical staining images for LDHA in ANCT and pathological differentiation of OSCC tissues. Magnification at 100× (left panel) and 200× (right panel). (B) Histological scoring of LDHA in ANCTs and OSCC tissues. (C) Histological scoring of LDHA in OSCC tissues with various pathological differentiations. (D) Histological scoring of LDHA in OSCC tissues with various TNM classifications. (E) Relative LDHA mRNA expression in ANCTs and OSCC tissues. (F) LDHA protein expression in six pairs of OSCC tissues and in non-tumor tissues were determined by Western blot analysis (left) and quantitatively analyzed (right). (G) Relative expression of LDHA in normal oral mucosal epithelial tissues and OSCC cell lines; (H) Relative expression of LDHA mRNA in OSCC tissues (n = 284) and matched ANCTs (n = 30) from TCGA database. (I) Kaplan–Meier survival curves of overall survival, disease-free survival, and disease-specific survival based on patients with OSCC with high- and low-expression LDHA. Differences between the two groups were compared using a log-rank test. The experiment was repeated three times; error bars indicate standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001.
Association between LDHA expression and clinicopathological features in patients with OSCC.
| Male | 58 | 35 | 23 | 0.0969 |
| Female | 31 | 13 | 18 | |
| ≥60 | 54 | 22 | 20 | 0.7813 |
| <60 | 35 | 26 | 21 | |
| Well | 42 | 16 | 26 | 0.0046 |
| Moderate + poor | 47 | 32 | 15 | |
| T1-2 | 75 | 37 | 38 | 0.0439 |
| T3-4 | 14 | 11 | 3 | |
| I-II | 60 | 29 | 31 | 0.1274 |
| III-IV | 29 | 19 | 10 | |
| N− | 69 | 35 | 34 | 0.2594 |
| N+ | 20 | 13 | 7 | |
Statistical method: Fisher's exact test.
Statistically significant: p < 0.05.
Proportion of positive cells (0–100%) and intensity of the cytoplasmic staining (0: no staining, 1: weak, 2: moderate, and 3: strong) were used to calculate the LDHA Histo-score. The score of each slice was determined using the staining index (proportion of positive cells × staining intensity) (H-score: 0–300). Tissues with an H-score >150 were classified as the high-expression group, whereas H-scores ≤ 150 were classified as the low-expression group.
Figure 2LDHA promotes malignant progression of OSCC by inducing EMT. (A,B) GO enrichment analysis of the target module genes, biological process analysis, and cellular component analysis. (C) KEGG enrichment analysis of the target module genes. (D) Epithelial-mesenchymal transition gene set with statistically significant differences in GSEA using Hallmark gene sets. (E,F) Western blot and RT-qPCR were used to detect the expression level of LDHA following transfection. (G,H) Western blot and RT-qPCR were used to detect the expression level of the EMT-related marker in stable LDHA-knockdown HSC3 and SCC15 cells. (I) Sections of tumor xenografts from shNS or shLDHA HSC3 cells subcutaneously injected nude mice were stained with LDHA, ZO1, E-cadherin, N-cadherin, Vimentin and Slug antibodies by IHC. Magnification at 200×. (J) HSC3 and SCC15 cells were treated with or without 10 ng/ml TGF-β for 48 h; the phenotypic changes of cells were recorded using microscopy. Magnification at 100×. (K) The stable LDHA-knockdown HSC3 and SCC15 cells treated with or without 10 ng/ml TGF-β for 48 h, protein expression was determined by Western blot analysis. The experiment was repeated three times; error bars indicate standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 3Silencing LDHA inhibits the aerobic glycolysis, proliferation, migration, and invasion of OSCC. (A,B) Glucose consumption and lactate production of LDHA knockdown HSC3 and SCC15 cells. (C,D) Proliferation of LDHA-suppressed HSC3 and SCC15 cells was detected using CCK-8 and colony formation assays. (E) Wound-healing of HSC3 and SCC15 cells after silencing LDHA was recorded and quantitatively analyzed. (F) Migration and invasion assay of LDHA knockdown HSC3 and SCC15 cells were photographed and measured; (G) Knockdown of LDHA inhibited HSC3 cells growth in NOD/SCID mice. (H) The volume of tumor xenografts in NOD/SCID mice were calculated weekly. (I) The tumor weight was measured on day 28. The experiment was repeated three times; error bars indicate standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4Effects of oxamate on the biological function of OSCC cells. (A) LDH activity of HSC3 and SCC15 cells was shown after exposure to oxamate for 24 h. (B,C) HSC3 and SCC15 cells were treated with oxamate for 24 h; glucose consumption and lactate production were detected. (D,E) Proliferation of HSC3 and SCC15 cells was detected using CCK-8 and colony formation assays after exposure to oxamate for 24 h. (F) Wound-healing of HSC3 and SCC15 cells after exposure to oxamate for 24 h was recorded and quantitatively analyzed. (G) HSC3 and SCC15 cells were treated with oxamate for 24 h; migration and invasion assays were photographed and measured. The experiment was repeated three times; error bars indicate standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001.